Ferraro, M.G.; Iazzetti, F.; Bocchetti, M.; Riccardi, C.; Montesarchio, D.; Santamaria, R.; Misso, G.; Piccolo, M.; Irace, C.
Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer. Pharmaceutics 2025, 17, 918.
https://doi.org/10.3390/pharmaceutics17070918
AMA Style
Ferraro MG, Iazzetti F, Bocchetti M, Riccardi C, Montesarchio D, Santamaria R, Misso G, Piccolo M, Irace C.
Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer. Pharmaceutics. 2025; 17(7):918.
https://doi.org/10.3390/pharmaceutics17070918
Chicago/Turabian Style
Ferraro, Maria Grazia, Federica Iazzetti, Marco Bocchetti, Claudia Riccardi, Daniela Montesarchio, Rita Santamaria, Gabriella Misso, Marialuisa Piccolo, and Carlo Irace.
2025. "Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer" Pharmaceutics 17, no. 7: 918.
https://doi.org/10.3390/pharmaceutics17070918
APA Style
Ferraro, M. G., Iazzetti, F., Bocchetti, M., Riccardi, C., Montesarchio, D., Santamaria, R., Misso, G., Piccolo, M., & Irace, C.
(2025). Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer. Pharmaceutics, 17(7), 918.
https://doi.org/10.3390/pharmaceutics17070918